Announcement • Feb 11
Genvor, Inc. Announces the Publication of Peer-Reviewed Research Validated Its Proprietary Agm182 Antifungal Peptide Technology in Phytofrontiers Genvor Inc. announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology in PhytoFrontiers™?, a journal of the American Phytopathological Society. The study, conducted in collaboration with the United States Department of Agriculture's Agricultural Research Service (USDA-ARS), demonstrates that transgenic corn expressing AGM182 achieves significant pre-harvest resistance to Aspergillus flavus and aflatoxin contamination. Aflatoxins are naturally occurring toxic and carcinogenic compounds produced by Aspergillus flavus that contain corn and other crops, posing significant risks to human and animal health. Economic losses fromungal diseases in corn are substantial, with total annual U.S. losses estimated between $3 billion and $5 billion. Aflatoxin contamination alone has potential annual market impacts ranging from approximately $52 million in lower-risk years to $1.68 billion in high-risk years. The peer-reviewed publication follows Genvor's November 2025 announcement that the USPTO issued U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, co-assigned with the USDA. Together, the patent and publication provide both intellectual property protection and independent scientific validation of the technology's commercial potential. The research was conducted at the USDA-ARS Food and Feed Safety Research Unit at the Southern Regional Research Center in New Orleans, Louisiana, in collaboration with scientists from Tuskegee University and Genvor. The study builds on Genvor's over 7-year Cooperative Research and Development Agreement (CRADA) with the USDA-ARS, which focuses on developing corn varieties resistant to pre-harvest aflatoxin contamination. Announcement • Jan 28
Genvor, Inc. Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, Effective February 2, 2026 Genvor Inc. announced the appointment of Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. In this role, Dr. Stavrides will lead Genvor’s commercial strategy and execution, focusing on expanding strategic partnerships, licensing agreements, and collaboration opportunities with global agricultural companies. Dr. Stavrides brings more than 15 years of corporate experience in agrochemicals and biologicals, most recently serving as Global Product Management Lead, Biocontrols, at Syngenta. During his tenure, Dr. Stavrides and his team led the commercial evaluation of over 500 biological product concepts, managed over a dozen external collaborations, and oversaw over 50 product launches globally (microbials, extracts, pheromones), quadrupling revenues over a seven-year period. Previously, Dr. Stavrides held various global regulatory, strategy and marketing positions, in both agrochemicals and biocontrols. He has also served as company representative to the International Biocontrol Manufacturers Association (IBMA) for several years. Dr. Stavrides is a biochemist and also holds a Ph.D. in Genomics from Cambridge University (Human Genome Project) and an MBA from INSEAD. Announcement • Dec 12
Genvor Incorporated Auditor Raises 'Going Concern' Doubt Genvor Incorporated filed its 10-K on Dec 10, 2025 for the period ending Sep 30, 2025. In this report its auditor, Novogradac & Company LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 
